Skip to content

Cipira Pharma’s Pune C&F licence cancelled after illegal claim on Schedule‑H drug

By News Analysis India · · 1 min read

The Maharashtra Food and Drug Administration announced the cancellation of the C&F licence held by Cipira Pharma & Life Sciences Ltd, located in Wadki, Pune. The move stems from a June 2026 inspection that revealed the company had marketed Reactin Plus tablets with an unauthorised statement labeling the drug as an “analgesic and antipyretic.”

Reactin Plus is classified as a Schedule‑H medication, meaning it can be dispensed only with a valid prescription. The false claim breached the Drugs and Cosmetics Act, prompting the FDA to confiscate stock valued at ₹11.19 lakh and issue a recall order.

Despite the recall directive, the firm did not fully implement the required measures. Consequently, the FDA exercised its powers to terminate the C&F licence on August 27, 2026, signalling a tougher stance on pharmaceutical misbranding.

Officials emphasized that continued vigilance will be maintained to safeguard consumers and ensure that all medicines in the market meet safety and regulatory standards.